Lisata Therapeutics Announces First Patient Treated In The Cholangiocarcinoma Cohort Of The BOLSTER Trial Of LSTA1, A Novel Tumor-Targeting And Penetrating Peptide
Portfolio Pulse from Benzinga Newsdesk
Lisata Therapeutics, Inc. (NASDAQ:LSTA) has announced the treatment of the first patient in the cholangiocarcinoma cohort of the BOLSTER Trial. The trial is a Phase 2a, double-blind, placebo-controlled, multi-center, randomized study evaluating LSTA1 in patients with advanced solid tumors. The trial is expected to be completed in the second half of 2024.
October 24, 2023 | 12:17 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Lisata Therapeutics has started the treatment of the first patient in the cholangiocarcinoma cohort of the BOLSTER Trial. This could potentially lead to positive results for the company's LSTA1 therapy.
The initiation of the treatment of the first patient in the cholangiocarcinoma cohort of the BOLSTER Trial is a significant step for Lisata Therapeutics. If the trial results are positive, it could potentially lead to the approval of LSTA1 therapy, which would be a significant boost for the company.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 100